Literature DB >> 2028833

Calcium regulation of parathyroid and C cell function in familial benign hypercalcemia.

M M Rajala1, G G Klee, H Heath.   

Abstract

The roles of parathyroid hormone (PTH) and calcitonin (CT) in the pathogenesis of familial benign hypercalcemia (FBH, or hypocalciuric hypercalcemia) are uncertain. Thus we performed studies in 26 patients with FBH, 12 patients with primary hyperparathyroidism (HPT), and 20 normal volunteers, to answer these questions: are plasma levels of intact or biologically active PTH frequently elevated in FBH? Is plasma intact PTH nonsuppressible during calcium infusion? Is there blunting of the C cell CT response to calcium infusion as occurs in primary HPT? We used three methods for measurement of PTH: a mid region-specific radioimmunoassay (iPTH, antiserum GP-1M), an extraction-concentration bioassay (bioPTH, stimulation of cAMP generation in osteoblastlike cells), and a two-site immunoradiometric assay (IRMA) for intact PTH. PTH levels were significantly elevated in primary HPT by all three methods, but mean PTH was normal in FBH and 85-92% of values overlapped the normal range. During 5 minute calcium infusions (2 mg Ca2+ per kg) iPTH values fell little, but bioPTH and intact PTH fell sharply in all three groups. Mean calcium-induced decreases of intact and bioPTH were indistinguishable from normal in FBH, but PTH levels generally remained elevated at 5 minutes in primary HPT. In FBH basal and postinfusion CT levels were normal. The data show that, in the majority of patients with FBH, PTH concentrations and bioactivity in blood are within the normal range and are suppressed rapidly to very low levels with further increases of calcium. The data suggest that the abnormality of parathyroid function in FBH differs from that in primary HPT.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2028833     DOI: 10.1002/jbmr.5650060204

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  4 in total

1.  Familial hypocalciuric hypercalcemia: new mutation in the CASR gene converting valine 697 to methionine.

Authors:  Cristina Aparicio López; Pilar Anton-Martin; Belén Gil-Fournier; Soraya Ramiro-León; Gustavo Pérez-Nanclares; Guiomar Pérez de Nanclares; Beatriz Martínez Menéndez; Luis Castaño
Journal:  Eur J Pediatr       Date:  2011-06-04       Impact factor: 3.183

2.  A case report of familial benign hypocalciuric hypercalcemia: a mutation in the calcium-sensing receptor gene.

Authors:  Seong Ill Woo; Hyunju Song; Kyung Eun Song; Dae Jung Kim; Kwan Woo Lee; Se Joong Kim; Yoon-Sok Chung
Journal:  Yonsei Med J       Date:  2006-04-30       Impact factor: 2.759

Review 3.  Familial benign hypercalcemia--from clinical description to molecular genetics.

Authors:  H Heath
Journal:  West J Med       Date:  1994-06

4.  Physiological studies in heterozygous calcium sensing receptor (CaSR) gene-ablated mice confirm that the CaSR regulates calcitonin release in vivo.

Authors:  Neva J Fudge; Christopher S Kovacs
Journal:  BMC Physiol       Date:  2004-04-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.